The regulatory roles of B cell subsets in transplantation

References

• Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11(7):1359–1367.
   PubMed Web of Science ®Google Scholar
• Dijke EI, Platt JL, Blair P, et al. B cells in transplantation. J Heart Lung Transplant. 2016;35(6):704–710.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010;1183:38–57.
   PubMed Web of Science ®Google Scholar
• Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221–241.
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Healy LM, et al. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front Immunol. 2015;6:626.
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–6099.
   PubMed Web of Science ®Google Scholar
• Tian J, Zekzer D, Hanssen L, et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol. 2001;167(2):1081–1089.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Li R, Rezk A, et al. A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]. PLoS One. 2014;9(8):e105421.
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166.
   PubMed Web of Science ®Google Scholar
• Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5):1001–1010.
   PubMed Web of Science ®Google Scholar
• Katz SI, Parker D, Turk JL. B-cell suppression of delayed hypersensitivity reactions. Nature. 1974;251(5475):550–551.
   PubMed Web of Science ®Google Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56(8):2715–2718.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):205–216.
   PubMedGoogle Scholar
• Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13(11):1365–1368.
   PubMed Web of Science ®Google Scholar
• Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94–98.
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–370.
   PubMed Web of Science ®Google Scholar
• Ding Q, Yeung M, Camirand G, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest. 2011;121(9):3645–3656.
   PubMed Web of Science ®Google Scholar
• Xiao S, Brooks CR, Zhu C, et al. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A. 2012;109(30):12105–12110.
   PubMed Web of Science ®Google Scholar
• Xiao S, Brooks CR, Sobel RA, et al. Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation. J Immunol. 2015;194(4):1602–1608.
   PubMed Web of Science ®Google Scholar
• Yeung MY, Ding Q, Brooks CR, et al. TIM-1 signaling is required for maintenance and induction of regulatory B cells. Am J Transplant. 2015;15(4):942–953.
   PubMed Web of Science ®Google Scholar
• Shi BY, Xiao L, Gao Y, et al. [Identification and functional study of Tim-1(+)CD19(+) regulatory B cell in kidney transplantation recipients]. Zhonghua Yi Xue Za Zhi. 2011;91(48):3388–3392.
   PubMedGoogle Scholar
• Liu J, Zhan W, Kim CJ, et al. IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One. 2014;9(2):e89236.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Haas KM, et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639–650.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, et al. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009;182(12):7459–7472.
   PubMed Web of Science ®Google Scholar
• Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007;178(12):7868–7878.
   PubMed Web of Science ®Google Scholar
• Schioppa T, Moore R, Thompson RG, et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(26):10662–10667.
   PubMed Web of Science ®Google Scholar
• Amu S, Saunders SP, Kronenberg M, et al. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010;125(5):1114–1124 e8.
   PubMed Web of Science ®Google Scholar
• Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186(10):5569–5579.
   PubMed Web of Science ®Google Scholar
• Sayi A, Kohler E, Toller IM, et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186(2):878–890.
   PubMed Web of Science ®Google Scholar
• Bankoti R, Gupta K, Levchenko A, et al. Marginal zone B cells regulate antigen-specific T cell responses during infection. J Immunol. 2012;188(8):3961–3971.
   PubMed Web of Science ®Google Scholar
• Rafei M, Hsieh J, Zehntner S, et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med. 2009;15(9):1038–1045.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Baba A, Yokota T, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity. 2014;41(6):1040–1051.
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264–268.
   PubMed Web of Science ®Google Scholar
• Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014;20(6):633–641.
   PubMed Web of Science ®Google Scholar
• Baumgarth N. B-1 cell heterogeneity and the regulation of natural and antigen-induced IgM production. Front Immunol. 2016;7:324.
   PubMed Web of Science ®Google Scholar
• O’Garra A, Chang R, Go N, et al. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol. 1992;22(3):711–717.
   PubMed Web of Science ®Google Scholar
• Durand J, Chiffoleau E. B cells with regulatory properties in transplantation tolerance. World J Transplant. 2015;5(4):196–208.
   PubMedGoogle Scholar
• Zhang X, Deriaud E, Jiao X, et al. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med. 2007;204(5):1107–1118.
   PubMed Web of Science ®Google Scholar
• Lundy SK, Boros DL. Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10. Infect Immun. 2002;70(2):812–819.
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Mizoguchi E, Sugimoto K, et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol. 2008;20(6):729–737.
   PubMed Web of Science ®Google Scholar
• Alam MS, Costales MG, Cavanaugh C, et al. Extracellular adenosine generation in the regulation of pro-inflammatory responses and pathogen colonization. Biomolecules. 2015;5(2):775–792.
   PubMed Web of Science ®Google Scholar
• Kaku H, Cheng KF, Al-Abed Y, et al. A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol. 2014;193(12):5904–5913.
   PubMed Web of Science ®Google Scholar
• Khan AR, Hams E, Floudas A, et al. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6:5997.
   PubMed Web of Science ®Google Scholar
• Braza F, Chesne J, Castagnet S, et al. Regulatory functions of B cells in allergic diseases. Allergy. 2014;69(11):1454–1463.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181.
   PubMed Web of Science ®Google Scholar
• Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10(11):1178–1184.
   PubMed Web of Science ®Google Scholar
• Deng S, Moore DJ, Huang X, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol. 2007;178(10):6028–6032.
   PubMed Web of Science ®Google Scholar
• Mann MK, Maresz K, Shriver LP, et al. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol. 2007;178(6):3447–3456.
   PubMed Web of Science ®Google Scholar
• Gray M, Miles K, Salter D, et al. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007;104(35):14080–14085.
   PubMed Web of Science ®Google Scholar
• Blair PA, Chavez-Rueda KA, Evans JG, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009;182(6):3492–3502.
   PubMed Web of Science ®Google Scholar
• Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32(1):129–140.
   PubMed Web of Science ®Google Scholar
• Stanic B, van de Veen W, Wirz OF, et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol. 2015;135(3):771–80 e8.
   PubMed Web of Science ®Google Scholar
• Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012;13(3):290–299.
   PubMed Web of Science ®Google Scholar
• Seyerl M, Kirchberger S, Majdic O, et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol. 2010;40(2):321–329.
   PubMed Web of Science ®Google Scholar
• Bobryshev YV, Sobenin IA, Orekhov AN, et al. Novel anti-inflammatory interleukin-35 as an emerging target for antiatherosclerotic therapy. Curr Pharm Des. 2015;21(9):1147–1151.
   PubMed Web of Science ®Google Scholar
• Parekh VV, Prasad DV, Banerjee PP, et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol. 2003;170(12):5897–5911.
   PubMed Web of Science ®Google Scholar
• Lee KM, Stott RT, Zhao G, et al. TGF-beta-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol. 2014;44(6):1728–1736.
   PubMed Web of Science ®Google Scholar
• Natarajan P, Singh A, McNamara JT, et al. Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-beta, and co-localize with CD4+Foxp3+ T cells. Mucosal Immunol. 2012;5(6):691–701.
   PubMed Web of Science ®Google Scholar
• Zhang HP, Wu Y, Liu J, et al. TSP1-producing B cells show immune regulatory property and suppress allergy-related mucosal inflammation. Sci Rep. 2013;3:3345.
   PubMed Web of Science ®Google Scholar
• Durand J, Huchet V, Merieau E, et al. Regulatory B cells with a partial defect in CD40 signaling and overexpressing granzyme B transfer allograft tolerance in rodents. J Immunol. 2015;195(10):5035–5044.
   PubMed Web of Science ®Google Scholar
• Lindner S, Dahlke K, Sontheimer K, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73(8):2468–2479.
   PubMed Web of Science ®Google Scholar
• Kaltenmeier C, Gawanbacht A, Beyer T, et al. CD4+ T cell-derived IL-21 and deprivation of CD40 signaling favor the in vivo development of granzyme B-expressing regulatory B cells in HIV patients. J Immunol. 2015;194(8):3768–3777.
   PubMed Web of Science ®Google Scholar
• Montandon R, Korniotis S, Layseca-Espinosa E, et al. Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc Natl Acad Sci U S A. 2013;110(24):E2199–E2208.
   PubMed Web of Science ®Google Scholar
• Lee KM, Kim JI, Stott R, et al. Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant. 2012;12(8):2072–2078.
   PubMed Web of Science ®Google Scholar
• Moreau A, Blair PA, Chai JG, et al. Transitional-2 B cells acquire regulatory function during tolerance induction and contribute to allograft survival. Eur J Immunol. 2015;45(3):843–853.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Griffiths R, Seshan SV, et al. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol. 2011;186(4):2643–2654.
   PubMed Web of Science ®Google Scholar
• Marino J, Paster JT, Trowell A, et al. B cell depletion with an anti-CD20 antibody enhances alloreactive memory T cell responses after transplantation. Am J Transplant. 2016;16(2):672–678.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum. 2008;58(1):5–14.
   PubMedGoogle Scholar
• Liu C, Noorchashm H, Sutter JA, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med. 2007;13(11):1295–1298.
   PubMed Web of Science ®Google Scholar
• Brouard S, Pallier A, Renaudin K, et al. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant. 2012;12(12):3296–3307.
   PubMed Web of Science ®Google Scholar
• Massart A, Pallier A, Pascual J, et al. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrol Dial Transplant. 2016;31(6):1002–1013.
   PubMed Web of Science ®Google Scholar
• Viklicky O, Krystufkova E, Brabcova I, et al. B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients. Transplantation. 2013;95(1):148–154.
   PubMed Web of Science ®Google Scholar
• Chesneau M, Michel L, Degauque N, et al. Regulatory B cells and tolerance in transplantation: from animal models to human. Front Immunol. 2013;4:497.
   PubMed Web of Science ®Google Scholar
• Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A. 2007;104(39):15448–15453.
   PubMed Web of Science ®Google Scholar
• Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1836–1847.
   PubMed Web of Science ®Google Scholar
• Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1848–1861.
   PubMed Web of Science ®Google Scholar
• Baron D, Ramstein G, Chesneau M, et al. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. Kidney Int. 2015;87(5):984–995.
   PubMed Web of Science ®Google Scholar
• Roedder S, Li L, Alonso MN, et al. A three-gene assay for monitoring immune quiescence in kidney transplantation. J Am Soc Nephrol. 2015;26(8):2042–2053.
   PubMed Web of Science ®Google Scholar
• Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012;122(1):368–382.
   PubMed Web of Science ®Google Scholar
• Lozano JJ, Pallier A, Martinez-Llordella M, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant. 2011;11(9):1916–1926.
   PubMed Web of Science ®Google Scholar
• Londono MC, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant. 2012;12(6):1370–1377.
   PubMed Web of Science ®Google Scholar
• Thaunat O. Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation. 2011;92(2):121–126.
   PubMed Web of Science ®Google Scholar
• Heidt S, Vergunst M, Anholts JD, et al. B cell markers of operational tolerance can discriminate acute kidney allograft rejection from stable graft function. Transplantation. 2015;99(5):1058–1064.
   PubMedGoogle Scholar
• Girmanova E, Hruba P, Viklicky O. Circulating biomarkers of tolerance. Transplant Rev (Orlando). 2015;29(2):68–72.
   PubMedGoogle Scholar
• Baron D, Giral M, Brouard S. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes. Transpl Int. 2015;28(8):938–959.
   PubMed Web of Science ®Google Scholar
• Rebollo-Mesa I, Nova-Lamperti E, Mobillo P, et al. Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment? Am J Transplant. 2016;16(12):3443–3457.
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando). 2010;24(2):67–78.
   PubMedGoogle Scholar
• Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70(6):887–895.
   PubMed Web of Science ®Google Scholar
• Shapiro R. Reducing antibody levels in patients undergoing transplantation. N Engl J Med. 2008;359(3):305–306.
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9(5):1099–1107.
   PubMed Web of Science ®Google Scholar
• Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009;4(12):1993–1997.
   PubMed Web of Science ®Google Scholar
• Brown CM, Abraham KA, O’Kelly P, et al. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc. 2009;41(9):3690–3692.
   PubMed Web of Science ®Google Scholar
• Slatinska J, Honsova E, Burgelova M, et al. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial. 2009;13(2):108–112.
   PubMed Web of Science ®Google Scholar
• Matlawska-Wasowska K, Ward E, Stevens S, et al. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia. 2013;27(6):1263–1274.
   PubMed Web of Science ®Google Scholar
• Seidel UJ, Schlegel P, Grosse-Hovest L, et al. Reduction of minimal residual disease in pediatric B-lineage acute lymphoblastic leukemia by an Fc-optimized CD19 antibody. Mol Ther. 2016;24(9):1634–1643.
   PubMed Web of Science ®Google Scholar
• Lang P, Feuchtinger T, Teltschik HM, et al. Improved immune recovery after transplantation of TCRalphabeta/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant. 2015;50(Suppl 2):S6–S10.
   PubMedGoogle Scholar
• Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation. Transplant Rev (Orlando). 2015;29(2):103–108.
   PubMedGoogle Scholar
• Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int. 2013;26(6):563–575.
   PubMed Web of Science ®Google Scholar
• Bradshaw SE. Transplantation: 5-year benefits of rituximab for ABO-mismatched renal grafts. Nat Rev Nephrol. 2011;7(5):245.
   PubMedGoogle Scholar
• Vogelbacher R, Meister S, Gückel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant. 2010;25(11):3764–3773.
   PubMed Web of Science ®Google Scholar
• Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010;89(11):1403–1410.
   PubMed Web of Science ®Google Scholar
• Fehr T, Rusi B, Fischer A, et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation. 2009;87(12):1837–1841.
   PubMed Web of Science ®Google Scholar
• Sautenet B, Blancho G, Buchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016;100(2):391–399.
   PubMed Web of Science ®Google Scholar
• Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009;87(9):1325–1329.
   PubMed Web of Science ®Google Scholar
• Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant. 2012;12(2):469–476.
   PubMed Web of Science ®Google Scholar
• Ikemiyagi M, Hirai T, Ishii R, et al. Transitional B cells predominantly reconstituted after a desensitization therapy using rituximab before kidney transplantation. Ther Apher Dial. 2017;21(2):139–149.
   PubMed Web of Science ®Google Scholar
• Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79(11):1507–1515.
   PubMed Web of Science ®Google Scholar
• Bächler K, Amico P, Hönger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant. 2010;10(5):1254–1262.
   PubMed Web of Science ®Google Scholar
• von Kutzleben S, Pryce G, Giovannoni G, et al. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology. 2017;150(4):444–455.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80(8):1051–1059.
   PubMed Web of Science ®Google Scholar
• Calne RY. Prope tolerance with alemtuzumab. Liver Transpl. 2005;11(3):361–363.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76(1):120–129.
   PubMed Web of Science ®Google Scholar
• Crepin T, Carron C, Roubiou C, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015;15(4):1028–1038.
   PubMed Web of Science ®Google Scholar
• Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22(5):504–509.
   PubMed Web of Science ®Google Scholar
• Kwun J, Page E, Hong JJ, et al. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transplant. 2015;15(3):815–822.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Cutler AJ, Brownlie RJ, et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8(4):419–429.
   PubMed Web of Science ®Google Scholar
• Zhou P, Comenzo RL, Olshen AB, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood. 2008;111(7):3403–3406.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74.
   PubMed Web of Science ®Google Scholar
• Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjogren’s syndrome. Rheumatology (Oxford). 2015;54(2):219–230.
   PubMed Web of Science ®Google Scholar
• Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):150.
   PubMed Web of Science ®Google Scholar
• Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant. 2009;14(6):662–666.
   PubMed Web of Science ®Google Scholar
• Sadaka B, Alloway RR, Shields AR, et al. Proteasome inhibition for antibody-mediated allograft rejection. Semin Hematol. 2012;49(3):263–269.
   PubMed Web of Science ®Google Scholar
• Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89(3):277–284.
   PubMed Web of Science ®Google Scholar
• Shah N, Meouchy J, Qazi Y. Bortezomib in kidney transplantation. Curr Opin Organ Transplant. 2015;20(6):652–656.
   PubMed Web of Science ®Google Scholar
• Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation. 2010;90(2):221–222.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Choi J, Kim I, et al. Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101(1):32–44.
   PubMed Web of Science ®Google Scholar
• Wu G, Chai N, Kim I, et al. Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol. 2013;28(2–3):138–143.
   PubMed Web of Science ®Google Scholar
• Kim I, Wu G, Chai NN, et al. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation. 2014;98(12):1262–1270.
   PubMed Web of Science ®Google Scholar
• Booth AJ, Grabauskiene S, Wood SC, et al. IL-6 promotes cardiac graft rejection mediated by CD4+ cells. J Immunol. 2011;187(11):5764–5771.
   PubMed Web of Science ®Google Scholar
• Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356–2363.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442–453.
   Google Scholar
• Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180(7):4763–4773.
   PubMed Web of Science ®Google Scholar
• Sicard A, Koenig A, Morelon E, et al. Cell therapy to induce allograft tolerance: time to switch to plan B? Front Immunol. 2015;6:149.
   PubMed Web of Science ®Google Scholar
• Zambidis ET, Barth RK, Scott DW. Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J Immunol. 1997;158(5):2174–2182.
   PubMed Web of Science ®Google Scholar
• Skupsky J, Zhang AH, Su Y, et al. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther. 2010;18(8):1527–1535.
   PubMed Web of Science ®Google Scholar
• Melo ME, Qian J, El-Amine M, et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol. 2002;168(9):4788–4795.
   PubMed Web of Science ®Google Scholar
• Scott DW. Transduced B cells: B is for ‘beneficial’! Eur J Immunol. 2011;41(6):1528–1530.
   PubMed Web of Science ®Google Scholar
• Satpute SR, Soukhareva N, Scott DW, et al. Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheum. 2007;56(5):1490–1496.
   PubMedGoogle Scholar
• Agarwal RK, Kang Y, Zambidis E, et al. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest. 2000;106(2):245–252.
   PubMed Web of Science ®Google Scholar
• Scott DW. Gene therapy for immunological tolerance: using ‘transgenic’ B cells to treat inhibitor formation. Haemophilia. 2010;16(102):89–94.
   PubMedGoogle Scholar
• Kang Y, Melo M, Deng E, et al. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci U S A. 1999;96(15):8609–8614.
   PubMed Web of Science ®Google Scholar
• El-Amine M, Melo M, Kang Y, et al. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol. 2000;165(10):5631–5636.
   PubMed Web of Science ®Google Scholar
• Su Y, Carey G, Maric M, et al. B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway. J Immunol. 2008;181(2):1153–1160.
   PubMed Web of Science ®Google Scholar
• Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005;105(12):4865–4870.
   PubMed Web of Science ®Google Scholar
• Litzinger MT, Su Y, Lei TC, et al. Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction. J Immunol. 2005;175(2):780–787.
   PubMed Web of Science ®Google Scholar
• Calderón-Gómez E, Lampropoulou V, Shen P, et al. Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis. Eur J Immunol. 2011;41(6):1696–1708.
   PubMed Web of Science ®Google Scholar